A socially oriented non-financial development institution and a major organizer of international conventions; exhibitions; and business, public, sporting, and cultural events. It was established in pursuance of a decision by the President of the Russian Federation.

The Roscongress Foundation is a socially oriented non-financial development institution and a major organizer of international conventions; exhibitions; and business, public, sporting, and cultural events. It was established in pursuance of a decision by the President of the Russian Federation.

The Foundation was established in 2007 with the aim of facilitating the development of Russia’s economic potential, promoting its national interests, and strengthening the country’s image. One of the roles of the Foundation is to comprehensively evaluate, analyse, and cover issues on the Russian and global economic agendas. It also offers administrative services, provides promotional support for business projects and attracting investment, and helps foster social entrepreneurship and charitable initiatives.

Each year, the Foundation’s events draw participants from 208 countries and territories, with more than 15,000 media representatives working on-site at Roscongress’ various venues. The Foundation benefits from analytical and professional expertise provided by 5000 people working in Russia and abroad. In addition, it works in close cooperation with 133 economic partners; industrialists’ and entrepreneurs’ unions; and financial, trade, and business associations from 70 countries worldwide.

RC personal account
Восстановление пароля
Введите адрес электронной почты или телефон, указанные при регистрации. Вам будет отправлена инструкция по восстановлению пароля.
Некорректный формат электронной почты или телефона
About

Online business breakfast ‘What Challenges Lay Ahead for the Government and the Pharmaceutical Industry During This Period?’ will take place on 2 June 2020 at 10:00. The event will focus on the response of the pharmaceutical industry to the challenges of the coronavirus pandemic in the context of government support measures for the industry. The Roscongress Foundation and the Content Foundation for the Development of Expert and Analytical Activity organize the event. The business breakfast will take place with the support of the Subcommittee on the Circulation of Medicine and the Development of the Pharmaceutical and Medical Industries under the State Duma Committee on Health Protection. The CDA agency is the organizing partner of the event.

A business breakfast with representatives of government, community and the pharmaceutical industry is an integral part of the St. Petersburg International Economic Forum programme. In the context of the coronavirus pandemic, the Roscongress Foundation carries on the tradition and holds a business breakfast in a new online format on the traditional days of the SPIEF.

The event will be attended by First Deputy Minister of Industry and Trade of the Russian Federation Sergey Tsyb, Head of the Federal Service for Surveillance in Healthcare (Roszdravnadzor) Alla Samoylova, Director of the Department of Drug Supply and Regulation of Medical Devices at the Ministry of Health of the Russian Federation Elena Maksimkina, Head of the Federal Service for Intellectual Property Grigory Ivliev, Deputy Director of the Department of Pharmaceutical and Medical Device Industry Development of the ‎Ministry of Industry and Trade of the Russian Federation Aleksey Alekhin, General Director Merck Russia and CIS Matthias Wernicke, as well as representatives of the pharmaceutical industry. Aleksandr Petrov, the Chairman of the Subcommittee on the Circulation of Medicine and the Development of the Pharmaceutical and Medical Industries, the Committee on Health Protection of the State Duma of the Russian Federation will moderate the business breakfast.

Participants of the business breakfast will discuss government support for the pharmaceutical industry, strategies to reduce the risks of a possible crisis of pharmaceutical ingredients and disruptions in the supply of drugs from abroad due to localization of production, issues related to medicines labelling, and prospects for the new drugs on the market.

Contacts